Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 93Lymphoid 25Other hematologic neoplasm 16Genitourinary 3Sarcoma 2Breast 2Tumor-Agnostic 1Myeloid 1CNS 1

Conditions

Glioblastoma 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × ixazomib × CNS × Clear all
NCT02630030 2021-03-26

Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma

Emory University

Phase EARLY_PHASE1 Completed
3 enrolled 10 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡